Use of Adjunctive Therapy in Acute Kawasaki Disease in Latin America

Simple item page
dc.article.number442
dc.catalogadorjca
dc.contributor.authorFortuna-Reyna, Brenda
dc.contributor.authorBainto, Emelia V.
dc.contributor.authorUlloa-Gutiérrez, Rolando
dc.contributor.authorGarrido-García, Luis M.
dc.contributor.authorEstripeaut, Dora
dc.contributor.authordel Águila, Olguita
dc.contributor.authorGómez, Virgen
dc.contributor.authorFaugier-Fuentes, Enrique
dc.contributor.authorMiño-León, Greta
dc.contributor.authorBeltrán, Sandra
dc.contributor.authorCofré, Fernanda
dc.contributor.authorChacón-Cruz, Enrique
dc.contributor.authorSaltigeral-Simental, Patricia
dc.contributor.authorMartínez-Medina, Lucila
dc.contributor.authorDueñas, Lourdes
dc.contributor.authorLuciani, Kathia
dc.contributor.authorRodríguez-Quiroz, Francisco J.
dc.contributor.authorCamacho-Moreno, Germán
dc.contributor.authorViviani, Tamara
dc.contributor.authorÁlvarez-Olmos, Martha I.
dc.contributor.authorde Sousa Marques, Heloisa Helena
dc.contributor.authorLópez-Medina, Eduardo
dc.contributor.authorPirez, María C.
dc.contributor.authorTremoulet, Adriana H.
dc.contributor.authorKawasaki Disease REKAMLATINA Network Study Group
dc.contributor.otherBorzutzky Schachter, Arturo
dc.date.accessioned2023-01-19T14:42:02Z
dc.date.available2023-01-19T14:42:02Z
dc.date.issued2020
dc.description.abstractObjective: To characterize the use of adjunctive therapy in Kawasaki disease (KD) in Latin America. Methods: The study included 1,418 patients from the Latin American KD Network (REKAMLATINA) treated for KD between January 1, 2009, and May 31, 2017. Results: Of these patients, 1,152 received only a single dose of IVIG, and 266 received additional treatment. Age at onset was similar in both groups (median 2 vs. 2.2 years, respectively). The majority of patients were male (58 vs. 63.9%) and were hospitalized with the first 10 days of fever (85.1 vs. 84.2%). The most common adjunctive therapy administered was steroids for IVIG-resistance, followed by additional doses of IVIG. The use of biologics such as infliximab was limited. KD patients who received adjunctive therapy were more likely to have a lower platelet count and albumin level as well as a higher Z score of the coronary arteries. Conclusion: This is the first report of adjunctive therapies for KD across Latin America. IVIG continues to be the initial and resistance treatment, however, steroids are also used and to a lesser extent, biological therapy such as infliximab. Future studies should address the barriers to therapy in children with acute KD throughout Latin America
dc.fechaingreso.objetodigital2023-01-19
dc.fuente.origenSIPA
dc.identifier.doi10.3389/fped.2020.00442
dc.identifier.eissn2296-2360
dc.identifier.urihttps://doi.org/10.3389/fped.2020.00442
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/66380
dc.information.autorucFacultad de medicina ; Borzutzky Schachter, Arturo ; 0000-0002-7904-262X ; 5897
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final7
dc.pagina.inicio1
dc.revistaFrontiers in Pediatrics
dc.rightsacceso abierto
dc.subjectKawasaki disease
dc.subjectLatin America
dc.subjectSteroids
dc.subjectInfliximab
dc.subjectAdjunctive therapy
dc.titleUse of Adjunctive Therapy in Acute Kawasaki Disease in Latin America
dc.typeartículo
dc.volumen8
sipa.codpersvinculados5897
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fped-08-00442 (1).pdf
Size:
381.06 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas